Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.

European journal of clinical pharmacology - 1 Feb 2013

Wu Jia, Jia Li-Tao, Shao Li-Ming, Chen Jia-Min, Zhong Dan-Dan, Xu Song, Cai Jian-Ting

Abstract excerpt

PURPOSE: This study was aimed to determine the impact of rabeprazole (RBRZ) on the antiplatelet efficacy of clopidogrel (CPG) in healthy Chinese volunteers, and further to predict the effect of CYP2C19 genetic polymorphism on the efficacy of rabeprazole and clopidogrel. METHODS: The open-label, two period cross-over study was conducted in 20 healthy Chinese subjects with different CYP2C19 genotypes receiving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Proton Pump Inhibitors

Share to Rabeprazole

Share to Ticlopidine

Source

Identifiers

PMID: 22706585
DOI: 10.1007/s00228-012-1329-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.PMID 22706585Read ↗

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.Semantic proximity Read ↗

CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration.Semantic proximity Read ↗

Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.Semantic proximity Read ↗

Influence of genetic and non-genetic factors on the plasma concentrations of the clopidogrel metabolite (SR26334) among Chinese patients.Semantic proximity Read ↗

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity Read ↗

Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.Semantic proximity Read ↗

Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.Semantic proximity Read ↗

Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.Semantic proximity Read ↗

Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.